Israel's Ministry of Health Approves Pluristem's Commercial-Scale 3D Cell Manufacturing Process Used at Its New Haifa Facility
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, announced today that it has completed the approval process and received final clearance from a fifth regulatory agency for its 3D cell therapy manufacturing processes in use at its new facility in Haifa. The latest approval comes from Israel's Ministry of Health and follows similar clearances from the U.S. Food and Drug Administration, the European Union 's Qualified Person, Germany 's Paul Ehrlich Institute, and the South Korean Ministry of...
View full press release